Efficacy and safety of novel oral anticoagulants in clinical practice: A report from three centers in Sweden

Thrombosis Journal

Volumn 12, Issue 1, 2014, Pages

  Labaf, Ashkan ^a,b   Carlwe, Martin ^c   Svensson, Peter J ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Region of Halland   (Sweden)

Author keywords

Atrial fibrillation; Dabigatran; Major bleeding; Novel oral anticoagulants; Thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTERIOVENOUS FISTULA; ARTICLE; BRAIN ISCHEMIA; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; INTRAOCULAR HEMORRHAGE; MEDICAL RECORD REVIEW; MUSCLE HEMATOMA; PLASMAPHERESIS; REGISTER; SUBDURAL HEMATOMA; SWEDEN; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; UNIVERSITY HOSPITAL; UNSPECIFIED SIDE EFFECT; WOUND;

EID: 84924107218     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/s12959-014-0029-6     Document Type: Article

References (16)

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, Committee R-LS, Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
2. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, Investigators RA: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 883:891.
3. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, et al: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
4. Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, Lip GY: Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013, 61:2264-2273.
5. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Guidelines ESCCfP: 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012, 33:2719-2747.
6. Poulsen BK, Grove EL, Husted SE: New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs 2012, 72:1739-1753.
7. Wieloch M, Sjalander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ: Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J 2011, 32:2282-2289.
8. Taylor J: Third universal definition of myocardial infarction. Eur Heart J 2012, 33:2506-2507.
9. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis: Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemostasis 2005, 3:692-694.
10. Bjork J, Grubb A, Sterner G, Nyman U: Revised equations for estimating glomerular filtration rate based on the Lund-Malmo Study cohort. Scand J Clin Lab Invest 2011, 71:232-239.
11. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S: Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011, 123:2363-2372.
12. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ, investigators R-L: Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010, 376:975-983.
13. Hazell L, Shakir SA: Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006, 29:385-396.
14. Yap LB, Rusani BI, Umadevan D, Muhammad Z, Hussin A, Kaur S, Omar R: A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation. J Thromb Thrombolysis 2014, 38:39-44.
15. FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. [ http://www.fda.gov/Drugs/DrugSafety/ucm396470.htm ]
16. Sorensen R, Gislason G, Torp-Pedersen C, Olesen JB, Fosbol EL, Hvidtfeldt MW, Karasoy D, Lamberts M, Charlot M, Kober L, Weeke P, Lip GY, Hansen ML: Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open 2013, 3:e002758. doi:10.1136/bmjopen-2013-002758.